Abstract:Pre-cancerous cells are normally recognized and eliminated by immune cells. Cancer progresses only when this immunosurveillance system fails. Although immunotherapy has driven the most significant and exciting advances in cancer treatment in modern times, current approaches are running into barriers. An emerging area of interest includes evidence for rare but highly potent stem cell-like T cells. Stem-like T cells combine long-term persistence and high potency with immunological memory. Our recent findings reveal insights into the nature and regulation of stem-like T cells and their potential anticancer activity. Minimal residual disease (MRD) underlies therapeutic resistance, dictates treatment escalation, and predicts patient outcomes. We have shown that the Wnt and PI3K pathways promote the transformation of hematopoietic stem cells (HSCs) into chemoresistant leukemia stem cells (LSCs), which form the root of leukemia initiation and post-treatment recurrence. High-throughput screening revealed that LSCs could be targeted by low dose anthracycline treatment. Mechanistically, low dose, but not high dose anthracyclines indirectly target LSCs by inhibiting their unique properties of immune escape, allowing for their elimination by CD8+ T cells. We employed single-cell genomic and proteomic analysis to investigate immunological changes during development of HSCs, LSCs, and their progeny in response to low dose anthracycline treatment. While leukemia progression results in exhaustion of differentiated CD8+ T cells, stem-like T cells accumulate. However, low dose anthracycline treatment reverses this imbalance. Comparing MRD+ and MRD- patient samples, we found that differential proportions of stem-like T cells persist in the bone marrow of leukemia patients. While T cells of MRD- patients recover following chemotherapy induction, T cell recovery is severely attenuated in MRD+ patients. Furthermore, failure of immunological recovery is driven at least partially by a lack of stem-like T cells in MRD+ leukemia patients. Overall, our studies have revealed that low dose anthracyclines, in contrast to high dose, induce opposing, dichotomous effects on LSCs vs. HSCs and stem-like vs. differentiated T cells. Citation Format: Fang Tao, Sara McElroy, Jacqelyn Nemechek, Irina Pushel, John Szarejko, Santosh Khanal, Todd Bradley, Doug Myers, John M. Perry. Stem-like T cells maintain latent anticancer activity and underly therapy resistance [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 5557.

Pten Dependence Distinguishes Haematopoietic Stem Cells from Leukaemia-Initiating Cells

PTEN Maintains Haematopoietic Stem Cells and Acts in Lineage Choice and Leukaemia Prevention

Suppression of Leukemia Development Caused by Pten Loss

Multi-genetic Events Collaboratively Contribute to Pten -Null Leukaemia Stem-Cell Formation

Chemoresistant Leukemia-Initiating Cell Expansion is Inhibited by Targeting Oncogenic Self-Renewal

Pten Loss in Hematopoietic Stem Cells Leads to A Myeloproliferative Disorder

Overcoming Wnt–β-catenin Dependent Anticancer Therapy Resistance in Leukaemia Stem Cells

Pten Loss in the Bone Marrow Leads to G-CSF–mediated HSC Mobilization

Methods for Pten in Stem Cells and Cancer Stem Cells

PD-1 Signalling Defines and Protects Leukaemic Stem Cells from T Cell Receptor-Induced Cell Death in T Cell Acute Lymphoblastic Leukaemia

Phosphodiesterase 5/protein Kinase G Signal Governs Stemness of Prostate Cancer Stem Cells Through Hippo Pathway.

Pten In Regulating Hematopoiesis And Leukemogenesis

Shp2 and Pten Have Antagonistic Roles in Myeloproliferation but Cooperate to Promote Erythropoiesis in Mammals

Pten Is A Tumor Suppressor In Cml Stem Cells And Bcr-Abl-Induced Leukemias In Mice

Atp8a1 deletion increases the proliferative activity of hematopoietic stem cells by impairing PTEN function

Adaptive responses to mTOR gene targeting in hematopoietic stem cells reveal a proliferative mechanism evasive to mTOR inhibition.

Hematopoietic and Leukemic Stem Cells Have Distinct Dependence on Tcf1 and Lef1 Transcription Factors

SHP-1 inhibition targets leukaemia stem cells to restore immunosurveillance and enhance chemosensitivity by metabolic reprogramming

Selective haematological cancer eradication with preserved haematopoiesis

TSC-mTOR maintains quiescence and function of hematopoietic stem cells by repressing mitochondrial biogenesis and reactive oxygen species.

Abstract 5557: Stem-like T cells maintain latent anticancer activity and underly therapy resistance